Our partnership Buchanan has been a trusted adviser to Genus since its IPO in 2000 on AIM. We have evolved Genus’ key message and communications needs in line with its corporate development and globalisation.
Growth story Genus has grown organically and by acquisition from £50m to more than £1.6bn in market capitalisation. Since 2014 alone, Genus has made six acquisitions and invested £100m in R&D, capital expenditure and acquisitions. This has included moving by acquisition into porcine genetics and the launch of a gene editing programme, that seeks to improve animal welfare.